| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0142(19850315)55:6<1327::AID-CNCR2820550628>3.0.CO;2-O |
| P698 | PubMed publication ID | 3871657 |
| P50 | author | Michael T Lotze | Q89121415 |
| Steven Rosenberg | Q2347448 | ||
| P2093 | author name string | Grimm EA | |
| Chu EW | |||
| Rayner AA | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunotherapy | Q1427096 |
| P1104 | number of pages | 7 | |
| P304 | page(s) | 1327-1333 | |
| P577 | publication date | 1985-03-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer | |
| P478 | volume | 55 |
| Q72801641 | A kindred with Griscelli disease: spectrum of neurological involvement |
| Q68098074 | Activation of swine peripheral blood lymphocytes with human recombinant interleukin-2 |
| Q69090313 | Adoptive immunotherapy with lymphokine-activated killer cells plus recombinant interleukin 2 in patients with unresectable hepatocellular carcinoma |
| Q59072375 | Advances and Prospects in Cancer Immunotherapy |
| Q43537382 | Augmentative effect of Nocardia rubra cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction |
| Q55715408 | Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. |
| Q54359503 | Cytokines and pancreatic cancer. The effect of rIFN-gamma, HuLeIFN, rTNF-alpha, and LAK-cells on pancreatic and other gastrointestinal tumors in vitro. |
| Q68780719 | Effect of host age upon interleukin-2-mediated anti-tumor responses in a murine fibrosarcoma model |
| Q45833763 | Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus |
| Q44098509 | Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials |
| Q35354010 | Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer |
| Q54388045 | Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells. |
| Q90167137 | Granzyme B Attenuates Bacterial Virulence by Targeting Secreted Factors |
| Q50004232 | IL-2 and Beyond in Cancer Immunotherapy |
| Q68485252 | Immunoregulation of lymphokine-activated killer cells |
| Q34684162 | Immunotherapy for pancreatic cancer: current concepts |
| Q40539148 | Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment |
| Q42038599 | Immunotherapy of hepatocellular carcinoma with autologous lymphokine-activated killer cells and/or recombinant interleukin-2. |
| Q68802117 | In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (r |
| Q69447291 | Induction of cytotoxicity from fresh splenocytes after in vivo administration of cyclophosphamide. Importance of long-term culture with high-dose recombinant interleukin-2 |
| Q73048395 | Interleukin-2 and cancer: critical analysis of results, problems and expectations |
| Q40832214 | Molecular approaches to cancer therapy. |
| Q92824998 | Novel Biomarkers for Personalized Cancer Immunotherapy |
| Q70053513 | Peripheral blood lymphocytes from thermal injury patients are defective in their ability to generate lymphokine-activated killer (LAK) cell activity |
| Q69215919 | Phenotypic and functional analysis of lymphokine-activated killer (LAK) cell clones. Ability of CD3+, LAK cell clones to produce interferon-gamma and tumor necrosis factor upon stimulation with tumor targets |
| Q39724074 | Potential uses of interleukin 2 in cancer therapy |
| Q40822468 | Psychoneuroimmunological issues in psycho-oncology |
| Q45790670 | Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer |
| Q37271951 | State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. |
| Q69743353 | Stimulation of peripheral blood lymphocytes with autologous tumor and serum-derived fractions from patients with laryngeal carcinomas |
| Q39037708 | Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy |
| Q36437768 | The Fas counterattack: a molecular mechanism of tumor immune privilege |
| Q39737942 | The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. |
| Q38657510 | The cellular immunotherapy of cancer: current and potential uses of interleukin-2. |
| Q35657649 | The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment |
| Q39550760 | The clinical potential of interleukin-2. |
| Q39512710 | The development of new immunotherapies for the treatment of cancer using interleukin-2. A review |
Search more.